Children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with the BCR-ABL1 fusion gene form a small patient group with a poor prognosis, which has been substantially improved in recent treatment protocols with the addition of imatinib and other tyrosine kinase inhibitors [1–2]. Here, BCR is linked to acute lymphoblastic leukemia.